Iovance Biotherapeutics Inc.’s stock fell sharply on heavier-than-usual volume on Wednesday, after the cancer-therapy company said the U.S. Food and Drug Administration placed a clinical hold on its trial for the lung-cancer treatment IOV-LUN-202.
Read Full Story
Latest posts by Market Watch (see all)
- Maine bars Trump from presidential primary ballot, citing insurrection clause - December 28, 2023
- These ETF strategies were big winners in 2023. Here’s where one CFRA analyst sees them going next year. - December 28, 2023
- Google settles $5 billion consumer-privacy lawsuit: report - December 28, 2023